Want to see GRDN full AI Analyst Report?
GRDN Stock Chart & Stats
$40.45
$1.01(2.50%)
At close: 4:00 PM EDT
$40.45
$1.01(2.50%)
Day’s Range― - ―
52-Week Range$23.14 - $47.02
Previous Close$41.46
Volume315.81K
Average Volume (3M)348.83K
Market Cap
$2.43B
Enterprise Value$2.63K
Total Cash (Recent Filing)$89.81M
Total Debt (Recent Filing)$35.24M
Price to Earnings (P/E)36.2
Beta0.57
Next Earnings
Nov 17, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.05
Shares Outstanding49,798,904
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)9.12
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$49.00Price Target Upside21.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.26
Revenue Forecast (FY)$1.41B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low trailing leverage materially reduces financial risk and increases resilience to sector shocks. A stronger capital base and lower interest burden give the company durable flexibility to invest in M&A, greenfields, or working capital needs and to absorb reimbursement headwinds without immediate liquidity stress.
Revenue Growth & Profitability ReboundSustained top-line acceleration and a return to operating profit indicate scalable core operations and improving unit economics. The rebound from a loss year to profitable results supports reinvestment and shows the business can convert growth into lasting profits if execution and margin trends continue.
Cash Generation & Financial FlexibilityStrong free cash flow and a healthy cash balance provide internal funding for organic expansion and smaller acquisitions without heavy reliance on debt. Combined with an extended revolver, this cash generation supports disciplined capital allocation and cushions timing effects from working capital or reimbursement shifts.
Bears Say
IRA Reimbursement PressureStructural reimbursement changes from the IRA materially depress reported revenue and introduce recurring uncertainty as additional tranches phase in. This is a durable industry headwind that can mute revenue growth and complicate long-range planning until the full impact of future tranches is known and mitigations are proven.
Integration & Margin DilutionGrowth via acquisitions and greenfields is diluting consolidated margins while new locations ramp. Persistent below-average margins at new assets can keep aggregate margins depressed for multiple quarters, creating execution risk and delaying the full profitability benefits of expansion strategies.
Profitability Volatility & Cash Conversion TimingInconsistent cash conversion and past swings in profitability reduce predictability of free cash generation. Working-capital timing effects mean earnings are less tightly coupled to cash, which can constrain financing options and magnify risks when reimbursement changes or integration costs hit simultaneously.
Guardian Pharmacy Services, Inc. Class A News
GRDN FAQ
What was Guardian Pharmacy Services, Inc. Class A’s price range in the past 12 months?
Guardian Pharmacy Services, Inc. Class A lowest stock price was $23.14 and its highest was $47.02 in the past 12 months.
What is Guardian Pharmacy Services, Inc. Class A’s market cap?
Guardian Pharmacy Services, Inc. Class A’s market cap is $2.43B.
When is Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date?
Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date is Nov 17, 2026 which is in 90 days.
How were Guardian Pharmacy Services, Inc. Class A’s earnings last quarter?
Guardian Pharmacy Services, Inc. Class A released its earnings results on Aug 06, 2026. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.262 by $0.028.
Is Guardian Pharmacy Services, Inc. Class A overvalued?
According to Wall Street analysts Guardian Pharmacy Services, Inc. Class A’s price is currently Undervalued.
Does Guardian Pharmacy Services, Inc. Class A pay dividends?
Guardian Pharmacy Services, Inc. Class A does not currently pay dividends.
What is Guardian Pharmacy Services, Inc. Class A’s EPS estimate?
Guardian Pharmacy Services, Inc. Class A’s EPS estimate is 0.32.
How many shares outstanding does Guardian Pharmacy Services, Inc. Class A have?
Guardian Pharmacy Services, Inc. Class A has 49,798,904 shares outstanding.
What happened to Guardian Pharmacy Services, Inc. Class A’s price movement after its last earnings report?
Guardian Pharmacy Services, Inc. Class A reported an EPS of $0.29 in its last earnings report, beating expectations of $0.262. Following the earnings report the stock price went up 11.046%.
Which hedge fund is a major shareholder of Guardian Pharmacy Services, Inc. Class A?
Currently, no hedge funds are holding shares in GRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardian Pharmacy Services, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (21.14% Upside)
$49.00 (21.14% Upside)
Blogger Sentiment
Bullish
GRDN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 249.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 17.8%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.48%
Trailing 12-Months
Company Description
Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.
GRDN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a positive operational and financial trajectory: strong adjusted EBITDA growth (23% YTD; 19% Q/Q), improved gross profit (+18% YoY), raised full-year guidance, robust clinical impact and disciplined capital allocation with nearly $90M cash and active M&A/greenfield expansion. Offsetting these positives are clear reimbursement headwinds from IRA pricing reductions that materially depressed reported revenue (Q2 +2%) and are expected to cause low single-digit reported declines in H2, continued margin dilution from ramping acquisitions/greenfields (though improving), and some cost pressures (fuel). Management emphasized mitigation actions, internal succession and disciplined deployment of capital, leaving the outlook upgraded but with ongoing uncertainty tied to future IRA tranches and integration ramps.View all GRDN earnings summariesGRDN Stock 12 Month Forecast
Average Price Target
$49.00
▲(21.14% Upside)